Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Several studies have shown that there is an increased risk of heart disease in people with
HIV. In this study the investigators are looking at the effect of Lovaza (Omega-3 fatty acid)
on improving endothelial function and decreasing inflammation which may contribute to this
increased risk. The investigators will also be doing studies to analyze coagulation and
inflammation markers.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborators:
Case Western Reserve University GlaxoSmithKline The Campbell Foundation